Payment overview · 2025
General Payments
$1,444.70
81 reported records · 14 companies
Healthcare provider profile · identity verified
Kyle Douglas Parish, MD
Allopathic & Osteopathic Physicians|Family Medicine|Sports Medicine · PADUCAH, KY · NPI 1881622751
Verified facts
What the public records show
CMS Open Payments records show Kyle Douglas Parish, MD received $1,444.70 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.36 | 17.1% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $220.66 | 15.3% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $173.97 | 12.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.06 | 11.3% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.23 | 10.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $104.69 | 7.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $68.06 | 4.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.64 | 4.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $62.29 | 4.3% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $59.39 | 4.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.19 | 3.2% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $44.21 | 3.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.05 | 1.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.90 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,444.70 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $220.66 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $179.22 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $165.55 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $128.32 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.55 | 11 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $115.86 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $87.71 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $87.71 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $66.64 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $62.29 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $59.39 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $58.11 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.60 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.78 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $46.19 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $46.01 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $46.01 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $46.01 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $44.21 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $44.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 65 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 165 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
65 | 65 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
165 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 69 |
| Losartan Potassium | Losartan Potassium | 255 | 74 |
| Lisinopril | Lisinopril | 247 | 73 |
| Furosemide | Furosemide | 237 | 53 |
| Gabapentin | Gabapentin | 235 | 56 |
| Meloxicam | Meloxicam | 207 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 60 |
| Alprazolam | Alprazolam | 182 | 31 |
| Carvedilol | Carvedilol | 175 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 40 |
| Montelukast Sodium | Montelukast Sodium | 172 | 49 |
| Omeprazole | Omeprazole | 166 | 47 |
| Eliquis | Apixaban | 165 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 157 | 46 |
| Trazodone Hcl | Trazodone Hcl | 154 | 41 |
| Metformin Hcl | Metformin Hcl | 150 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 32 |
| Farxiga | Dapagliflozin Propanediol | 126 | 20 |
| Sertraline Hcl | Sertraline Hcl | 126 | 29 |
| Spironolactone | Spironolactone | 125 | 32 |
| Bupropion Xl | Bupropion Hcl | 116 | 19 |
| Lorazepam | Lorazepam | 116 | 20 |
| Prednisone | Prednisone | 114 | 69 |
| Celecoxib | Celecoxib | 108 | 26 |
| Famotidine | Famotidine | 108 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 31 |
| Mirtazapine | Mirtazapine | 100 | 21 |
| Simvastatin | Simvastatin | 100 | 27 |
| Allopurinol | Allopurinol | 99 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 15 |
| Pregabalin | Pregabalin | 88 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 26 |
| Alendronate Sodium | Alendronate Sodium | 81 | 20 |
| Tramadol Hcl | Tramadol Hcl | 81 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 19 |
| Cefdinir | Cefdinir | 71 | 53 |
| Memantine Hcl | Memantine Hcl | 71 | 16 |
| Bumetanide | Bumetanide | 70 | 23 |
| Buspirone Hcl | Buspirone Hcl | 70 | 18 |
| Diazepam | Diazepam | 69 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 23 |
| Temazepam | Temazepam | 68 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 66 | 20 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 65 | 65 |
| Jardiance | Empagliflozin | 64 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 39 |
| Irbesartan | Irbesartan | 63 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 60 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 12 |
| Amoxicillin | Amoxicillin | 57 | 51 |
| Clonidine Hcl | Clonidine Hcl | 57 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 56 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 44 |
| Atenolol | Atenolol | 55 | 13 |
| Potassium Chloride | Potassium Chloride | 54 | 14 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Finasteride | Finasteride | 51 | 14 |
| Synthroid | Levothyroxine Sodium | 51 | 11 |
| Ezetimibe | Ezetimibe | 49 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | 16 |
| Azithromycin | Azithromycin | 47 | 40 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 37 |
| Eszopiclone | Eszopiclone | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 36 |
| Mupirocin | Mupirocin | 40 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 16 |
| Sucralfate | Sucralfate | 38 | 14 |
| Metolazone | Metolazone | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 27 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 31 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | suppressed |
| Entresto | Sacubitril/Valsartan | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 15 |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 17 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 12 |
| Linzess | Linaclotide | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 16 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Febuxostat | Febuxostat | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Ozempic | Semaglutide | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Terconazole | Terconazole | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxaprozin | Oxaprozin | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,444.70 · 81 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, Azstarys, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Symbravo, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error